Experimental Cannabis Medication Shows Promise in Reducing Chronic Back Pain
An experimental medication made from marijuana has shown significant promise in reducing chronic back pain, according to a recent study. The research, conducted by German drugmaker Vertanical, involved over 800 patients and demonstrated that the cannabis-based medication can effectively alleviate back pain, a common form of chronic pain. This breakthrough offers new hope for individuals suffering from this debilitating condition, which affects millions worldwide.
The study’s findings are particularly noteworthy, given the limited treatment options currently available for chronic back pain. Over-the-counter pain relievers, such as ibuprofen, can have severe side effects when used long-term, including stomach ulcers and indigestion. Opioids, which were once widely prescribed for pain management, are no longer recommended due to their high risk of addiction and contribution to the ongoing opioid epidemic.
Study Details and Results
The study, led by Dr. Matthias Karst, a pain specialist at Hannover Medical School, involved patients with chronic lower-back pain who were randomly assigned to receive either the cannabis-based medication or a placebo. The results showed that patients who received the medication experienced a nearly 2-point reduction in pain on an 11-point scale, compared to a 1.4-point reduction for those receiving the placebo. Additionally, patients who received the medication reported improvements in sleep and physical function.
The medication, which contains THC, the active ingredient in marijuana, was designed to have very low levels of the chemical, essentially a microdose. This approach minimized the risk of drug abuse, dependence, or withdrawal, with patients not showing any signs of these issues during the trial. However, driving was not recommended during the first few weeks of taking the medication, and patients were advised to exercise caution when operating vehicles.
Implications and Future Directions
The study’s results have significant implications for the treatment of chronic back pain, a condition that has few proven treatments. Vertanical is seeking approval for its medication, which could provide a much-needed alternative for patients who have not responded to traditional treatments. The company has filed an application with European regulators and is working closely with the US Food and Drug Administration (FDA) to design a study that will support FDA approval.
While more research is needed to fully understand the therapeutic potential of cannabis, this study contributes to the growing body of evidence supporting its use in pain management. Health officials in Canada and Europe have already approved pharmaceutical-grade cannabis for several types of pain, including nerve pain due to multiple sclerosis. In the US, the FDA has approved a drug containing CBD, a non-intoxicating chemical found in cannabis, to treat rare seizures in children with epilepsy.
For individuals suffering from chronic back pain, this new research offers a glimmer of hope. As the medical community continues to explore the therapeutic properties of cannabis, it is essential to approach this topic with a nuanced understanding of the available evidence and the need for further research. For more information on this breakthrough, visit Here
Image Source: www.twincities.com
